Galapagos (GLPG) AI Stock Analysis

• Market Cap: $2.18B
• Dividend Yield: N/A
• Average Volume (3M): 110.39K
• Price to Earnings (P/E): 5.7
• Beta (1Y): 0.75
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 704
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 13.99
• Shares Outstanding: 65,897,070
• 10 Day Avg. Volume: 99,472
• 30 Day Avg. Volume: 110,389
• PEG Ratio: 0.02
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 1.66
• P/FCF Ratio: -9.10
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 1.64
• Enterprise Value/Gross Profit: 2.93
• Enterprise Value/Ebitda: 6.24
• 1Y Price Target: $27.50
• Price Target Upside: -17.62% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.41
• Revenue Forecast (FY): $244.36M

• Rating: 68 Neutral
• Price Target: $37.00 ▲(10.84% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

GLPG scores strongest on financial positioning (very low leverage and large cash resources) and supported valuation (low P/E). The main offset is persistent negative operating/free cash flow and earnings quality concerns highlighted by non-recurring profit drivers and ongoing restructuring/wind-down cash needs; technical signals are broadly neutral.

Positive Factors

Very strong cash position

A ~EUR 3.0bn cash and financial investments balance gives Galapagos durable strategic optionality: it can fund near-term restructuring, business development, and GLPG3667 advancement without immediate financing. This materially lowers liquidity risk and supports deal-making over 2–6 months.

Clinical de‑risking of TYK2 program

A positive Phase II topline for GLPG3667 materially de‑risks a key immunology asset, improving its partnership and development optionality. Durable impact: stronger negotiating leverage for BD, clearer pathway to Phase III, and an asset that can underpin medium‑term revenue prospects if partnered or advanced.

Governance and business‑development expertise refreshed

A refreshed management team and board with transaction and deal expertise increases the likelihood of disciplined capital allocation and successful BD execution. Over months, improved governance should enhance deal sourcing, structuring and integration outcomes for pipeline monetization.

Negative Factors

Persistent operating cash burn

Despite strong liquidity, Galapagos continues to generate negative operating and free cash flow, creating ongoing reliance on its cash stockpile. This structural cash burn limits runway for organic expansion and forces prioritization of BD transactions or asset sales to sustain operations beyond 2026.

Earnings quality affected by one‑offs

The swing to reported operating profit in 2025 was driven largely by a one‑time deferred revenue release, masking underlying operational performance. This reduces earnings durability and complicates forecasting, making near‑term performance dependent on future non‑recurring items or successful BD execution.

Dependence on Gilead and partnership outcomes

Galapagos' strategy and potential monetization of GLPG3667 rely on partner cooperation and rights waivers from Gilead. That dependence creates execution risk: durable value capture hinges on successful external partnerships and negotiated economics, which may be constrained or temporary.

Galapagos Business Overview & Revenue Model

Company Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

How the Company Makes Money

Galapagos generates revenue primarily through collaboration agreements with major pharmaceutical companies, which often include upfront payments, milestone payments, and royalties on sales of developed products. A significant portion of its revenue is derived from strategic partnerships, notably with companies like Gilead Sciences, which has invested in Galapagos and collaborates on the development of drug candidates. The company's revenue model also includes potential income from licensing agreements and the commercialization of its proprietary drug candidates, should they receive regulatory approval.

Galapagos Financial Statement Overview

Summary

Strong balance sheet (very low leverage; high balance-sheet flexibility) and improved reported profitability with a sharp TTM revenue step-up support the score. Offsetting this, operating and free cash flow remain persistently negative (ongoing cash burn) and multi-year revenue/margin volatility raises questions about earnings sustainability and cash conversion.

Income Statement

TTM (Trailing-Twelve-Months) shows a sharp revenue step-up (up ~288%) with strong reported profitability (net margin ~29% and positive operating profit). However, the multi-year profile is volatile: revenue fell materially in 2022 and margins swung from deep losses (2020–2022) to profits (2023–TTM), suggesting earnings quality is less stable and may be influenced by non-recurring or variable sources typical in biotech.

Balance Sheet

Balance sheet is a clear strength: leverage is extremely low (debt-to-equity ~0.4% in TTM (Trailing-Twelve-Months)), and equity remains sizable versus assets. Returns improved meaningfully (ROE ~11% in TTM (Trailing-Twelve-Months) vs ~2.6% in 2024 and negative in 2020–2022), though the improvement comes after several weak years, so durability still needs to be proven.

Cash Flow

Cash generation remains a key weakness: operating cash flow and free cash flow are consistently negative across the entire period, including TTM (Trailing-Twelve-Months) (operating cash flow about -252M; free cash flow about -266M). While cash burn has moderated versus earlier years, the business is still not self-funding, creating ongoing dependence on the balance sheet and/or financing despite reported net profitability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.11B	275.65M	239.72M	241.25M	484.85M
Gross Profit	1.04B	240.79M	239.72M	241.25M	483.22M
EBITDA	556.98M	43.33M	51.04M	3.87M	-100.93M
Net Income	320.90M	74.08M	211.70M	-217.99M	-125.42M
Balance Sheet
Total Assets	3.41B	4.14B	4.36B	4.73B	5.19B
Cash, Cash Equivalents and Short-Term Investments	3.00B	3.12B	3.68B	4.09B	4.70B
Total Debt	12.10M	11.72M	9.60M	21.90M	26.86M
Total Liabilities	170.58M	1.24B	1.56B	2.21B	2.55B
Stockholders Equity	3.23B	2.90B	2.80B	2.53B	2.64B
Cash Flow
Free Cash Flow	-202.40M	-402.14M	-425.24M	-537.49M	-561.71M
Operating Cash Flow	-189.23M	-320.03M	-405.97M	-500.54M	-503.83M
Investing Cash Flow	219.35M	220.60M	71.19M	-1.25B	541.24M
Financing Cash Flow	-3.14M	-4.92M	-5.00M	-1.49M	-3.88M

Galapagos Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 33.38
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLPG, the sentiment is Neutral. The current price of 33.38 is below the 20-day moving average (MA) of 33.79, below the 50-day MA of 33.63, and above the 200-day MA of 31.94, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 46.60 is Neutral, neither overbought nor oversold. The STOCH value of 24.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GLPG.

Galapagos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLPG	68 Neutral	$2.18B	5.74	-16.45%	―	―	―
TARS	62 Neutral	$3.26B	-51.51	-23.39%	―	182.44%	47.21%
RXRX	53 Neutral	$1.84B	-2.84	-59.54%	―	-32.98%	-18.46%
AGIO	52 Neutral	$1.67B	-3.82	-30.20%	―	36.26%	-158.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TVTX	47 Neutral	$2.60B	-67.82	-57.80%	―	114.22%	77.02%
IRON	43 Neutral	$2.33B	―	-35.86%	―	―	-34.96%

Galapagos Corporate Events

Galapagos Posts 2025 Profit and Accelerates Strategic Exit from Cell Therapy

Galapagos reported its full-year 2025 results on February 23, 2026, highlighting a strategic reset centered on winding down its cell therapy business and pivoting to business development-led growth. The company closed 2025 with about €3.0 billion in cash and financial investments, expects 2026 year-end cash of €2.775–€2.85 billion, and aims to be cash flow neutral to positive by late 2026 after restructuring costs.

Management detailed that the wind-down of its cell therapy activities, formally initiated after works council consultations concluded on January 5, 2026, is on schedule and should be substantially completed by the end of the third quarter of 2026. The remaining organization is expected to be a lean team of 35–40 employees by end-2026, with Galapagos repositioned to pursue transformational deals in areas of high unmet medical need.

Governance changes in late 2025 included new executive and board appointments, such as a new General Counsel and several new non-executive directors, alongside the departure of multiple board members. These moves, together with the appointment of CEO Henry Gosebruch in May 2025 and further board refreshment in early 2026, underscore a broader governance overhaul intended to support the new strategic direction.

In its immunology portfolio, Galapagos reported that December 2025 topline Phase 2 data for TYK2 inhibitor GLPG3667 in dermatomyositis met its primary endpoint and showed meaningful improvements on multiple secondary measures with a favorable safety profile. In systemic lupus erythematosus, GLPG3667 did not achieve a statistically significant dose-response on the primary SRI-4 endpoint but delivered numerical benefits on several secondary, particularly skin-related, outcomes, with final 48-week data pending in the second quarter of 2026.

As part of the strategy to maximize value from its TYK2 program, the company is actively evaluating partnership and business development options to advance GLPG3667 in dermatomyositis and exploring expansion into additional severe autoimmune indications. In oncology, Galapagos has terminated its Phase 1/2 CAR-T trials ATALANTA-1 and PAPILIO-1 in connection with the cell therapy exit, with patients transitioning into the HESPERIA long-term follow-up study and only minimal residual spending anticipated.

Financially, Galapagos swung from an operating loss of €188.3 million in 2024 to an operating profit of €295.1 million in 2025, mainly driven by the release of €1.069 billion in deferred income from its drug discovery platform collaboration. Total net revenues surged 304% year-on-year to €1.112 billion, collaboration revenues climbed sharply, and the company reported net profit of €320.9 million versus €74.1 million in 2024, despite higher R&D and an impairment charge for the cell therapy activities.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Galapagos Adds Industry Veteran Paulo Fontoura to Board as Independent Director

Galapagos announced on February 19, 2026, that it has co-opted Dr. Paulo Fontoura as a Non-Executive Independent Director to its Board, effective February 9, 2026. He replaces Dr. Susanne Schaffert, who stepped down from the Board on November 1, 2025, marking a planned refresh of the company’s governance.

Dr. Fontoura brings two decades of pharmaceutical leadership, including senior roles at Roche and experience in launching breakthrough therapies and digital health tools such as smartphone-based clinical endpoints. His appointment is intended to strengthen strategic oversight as Galapagos pursues transformative business development and advances its pipeline of innovative medicines.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Galapagos Discloses Bank of America Crossing 5% Voting Rights Threshold

On February 10, 2026, Galapagos reported that Bank of America Corporation and its affiliates repeatedly crossed the 5% transparency threshold in the company’s voting rights in early February, triggering a series of regulatory notifications under Belgian disclosure rules. Between February 2 and February 5, 2026, Bank of America’s position in Galapagos’ shares and equivalent financial instruments rose as high as 7.23% of voting rights before being reduced to 5.04%, signaling active trading by a major financial institution but no change in Galapagos’ own capital structure.

The disclosure shows that on February 5, 2026, Bank of America and its affiliates held 132,087 direct voting rights and 3,191,854 equivalent financial instruments, together representing 5.04% of Galapagos’ 65,897,071 outstanding shares. For investors, the notifications highlight short-term shifts in derivative and equity exposure by a large banking group rather than a strategic stake-building move, providing transparency on ownership dynamics without indicating any direct operational impact on Galapagos.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Galapagos to Wind Down Global Cell Therapy Operations and Close Five Sites

On January 5, 2026, Galapagos NV announced that, following completion of required works council consultations in Belgium and the Netherlands, its board has formally decided to wind down the company’s cell therapy activities, a move first signaled on October 21, 2025 after a strategic review and unsuccessful divestment efforts. The shutdown will affect about 365 employees across Europe, the U.S. and China and entail closing facilities in Leiden, Basel, Princeton, Pittsburgh and Shanghai, while the company concentrates resources on its remaining non-cell therapy pipeline, including the GLPG3667 TYK2 program, and seeks to reposition itself for long-term growth through transformational business development, supported by a cash and investment position of roughly €3.0 billion as of December 31, 2025 and a streamlined geographic footprint centered on Mechelen, Chicago and San Francisco.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Galapagos Reports Mixed Late-Stage Results for TYK2 Inhibitor GLPG3667 and Eyes Partnerships After Dermatomyositis Win

On December 18, 2025, Galapagos reported topline data from two Phase 3-enabling trials of its selective TYK2 inhibitor GLPG3667, showing that the GALARISSO dermatomyositis study met its primary endpoint, with statistically significant improvement in Total Improvement Score at week 24 versus placebo using a pre-specified 10% significance level, alongside meaningful gains on multiple secondary disease-activity measures and a favorable safety and tolerability profile. In contrast, the GALACELA systemic lupus erythematosus trial did not reach statistical significance on its primary SRI-4 dose-response endpoint at week 32, although GLPG3667 showed numerical benefits over placebo on several secondary, particularly skin-related, outcomes; with Gilead temporarily waiving certain collaboration rights, Galapagos now plans to explore strategic options, including external partnerships, to accelerate further development of GLPG3667 in dermatomyositis and potentially other autoimmune indications, while awaiting full 48-week SLE data expected in 2026 to determine the future of that program.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Galapagos NV Announces Promising ATALANTA-1 Study Results Amid Plans to Wind Down Cell Therapy

On December 8, 2025, Galapagos NV presented new Phase 2 data from its ATALANTA-1 study at the American Society of Hematology Annual Meeting, showcasing promising results for its CAR T-cell therapy candidate, GLPG5101, in treating mantle cell lymphoma (MCL). The study demonstrated high complete response rates and minimal residual disease negativity, with a short 7-day vein-to-vein time, allowing more patients to access treatment. Despite these positive outcomes, Galapagos announced its intention to wind down its cell therapy activities, subject to consultations in Belgium and the Netherlands, while remaining open to potential acquisition proposals.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.